- ISIN
- US6031701013
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 10, 2023
Highlights
- Market Cap
- $1.88B
- Enterprise Value
- $1.77B
- EPS (TTM)
- -$1.95
- Gross Profit (TTM)
- -$28.00K
- EBITDA (TTM)
- -$167.25M
- Year Range
- $12.59 - $47.65
- Target Price
- $46.00
- ROA (TTM)
- -23.25%
- ROE (TTM)
- -23.78%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MLYS Performance Chart
Mineralys Therapeutics Inc. Common Stock (MLYS) is down 21.8% since the beginning of the year. At $28 per share, MLYS is trading 40.4% below its 52-week high of $48.
Loading charts...
Returns By Period
Mineralys Therapeutics Inc. Common Stock (MLYS) has returned -21.80% so far this year and 95.86% over the past 12 months.
Mineralys Therapeutics Inc. Common Stock
- 1D
- -2.00%
- 1M
- 20.15%
- 6M
- -14.95%
- YTD
- -21.80%
- 1Y
- 95.86%
- 3Y*
- 23.00%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.42%
- 1M
- 1.94%
- 6M
- 8.74%
- YTD
- 10.66%
- 1Y
- 21.02%
- 3Y*
- 19.50%
- 5Y*
- 11.63%
- 10Y*
- 13.41%
MLYS Monthly Returns History
Based on dividend-adjusted daily data since Feb 10, 2023, MLYS's average daily return is +0.15%, while the average monthly return is +3.45%. At this rate, an investment would double in approximately 1.7 years.
Historically, 43% of months were positive and 57% were negative. The best month was Sep 2025 with a return of +145.0%, while the worst month was Sep 2023 at -25.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.
On a daily basis, MLYS closed higher 47% of trading days. The best single day was Sep 2, 2025 with a return of +86.4%, while the worst single day was Aug 14, 2024 at -22.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.88% | -5.28% | -7.42% | -1.62% | 18.20% | -14.35% | 5.19% | -21.80% | |||||
| 2025 | -16.33% | -11.26% | 73.74% | -10.52% | 9.64% | -13.16% | 4.58% | 9.40% | 144.96% | 7.75% | 5.53% | -15.84% | 194.80% |
| 2024 | 26.86% | 40.97% | -16.06% | -5.11% | 4.24% | -8.38% | 5.90% | 0.16% | -2.42% | 10.49% | -4.56% | -3.60% | 43.14% |
| 2023 | -15.73% | -11.92% | -14.11% | 8.10% | 17.26% | -17.13% | -9.13% | -25.93% | -18.72% | -13.84% | 29.13% | -59.24% |
Benchmark Metrics
Mineralys Therapeutics Inc. Common Stock has an annualized alpha of 22.27%, beta of 0.96, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since February 10, 2023.
- This stock participated in 208.08% of S&P 500 Index downside but only 130.48% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 22.27%
- Beta
- 0.96
- R²
- 0.03
- Upside Capture
- 130.48%
- Downside Capture
- 208.08%
Return for Risk
Risk / Return Rank
MLYS ranks 80 for risk / return — better than 80% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Mineralys Therapeutics Inc. Common Stock (MLYS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MLYS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.76 | ||
| Sortino ratioReturn per unit of downside risk | +0.56 | ||
| Omega ratioGain probability vs. loss probability | 1.33 | 1.30 | +0.02 |
| Calmar ratioReturn relative to maximum drawdown | 1.80 | 2.28 | -0.48 |
| Martin ratioReturn relative to average drawdown | 3.13 | 9.88 | -6.75 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Mineralys Therapeutics Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Mineralys Therapeutics Inc. Common Stock was 71.75%, occurring on Nov 22, 2023. Recovery took 443 trading sessions.
The current Mineralys Therapeutics Inc. Common Stock drawdown is 40.04%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -71.75%Nov 2023 | 9mo 15d | 1y 9mo | 2y 6moFeb 2023 - Sep 2025 |
2026 bear market2026 | -52.46%Jun 2026 | 6mo 27d | — | 8mo 2dNov 2025 - now |
2025 correction2025 | -16.19%Nov 2025 | 16d | 4d | 20dOct 2025 - Nov 2025 |
2025 pullback2025 | -7.35%Oct 2025 | 5d | 2d | 7dOct 2025 - Oct 2025 |
2025 pullback2025 | -6.09%Sep 2025 | 4d | 3d | 7dSep 2025 - Sep 2025 |
Drawdown Indicators
| MLYS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -71.75% | -56.78% | -14.97% |
Max Drawdown (1Y)Largest decline over 1 year | -52.46% | -9.10% | -43.36% |
Max Drawdown (3Y)Largest decline over 3 years | -61.60% | -18.90% | -42.70% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -40.04% | -0.45% | -39.59% |
Average DrawdownAverage peak-to-trough decline | -36.44% | -10.71% | -25.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 30.07% | 2.09% | +27.98% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Mineralys Therapeutics Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Mineralys Therapeutics Inc. Common Stock is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MLYS in comparison with other companies in the Biotechnology industry. Currently, MLYS has a P/B value of 3.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MLYS
Add Mineralys Therapeutics Inc. Common Stock to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MLYS